Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 508

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 12
Chunk 508
---
) 
     - 
  
    Payment
    on convertible note payable 
     (150,000) 
     - 
  
    Proceeds
    from offering, net of offering costs 
     9,725,213  
     - 
  
    Proceeds
    from sale of common stock 
     150,000  
     55,000 
  
    Net
    cash provided by financing activities 
     7,652,036  
     445,000 

    Net
    Change in Cash 
     3,741,032  
     (35,953)

    Beginning
    of period 
     28,478  
     64,431 
  
    End
    of period 
    $3,769,510  
    $28,478 

    Supplemental
    disclosure of cash flow information: 

    Cash
    paid for interest 
    $147,776  
    $28,128 
  
    Cash
    paid for income taxes 
    $-  
    $- 

    Schedule
    of Non-Cash Investing and Financing Activities: 

    Convertible
    note issued as a settlement of a previously accrued liability 
    $-  
    $150,000 
  
    Restricted
    stock issued for forgiveness of salary 
    $10,000  
    $2,158,050 
  
    Stock
    options issued for forgiveness of salary 
    $50,000  
    $2,614,790 
  
    Note
    payable, related party assigned to Note payable 
    $266,667  
    $- 
  
    Stock
    issued for exercise of options in exchange for note payable, related parties 
    $-  
    $100,000 
  
    Discount
    on convertible note payable 
    $-  
    $60,000 
  
    Stock issued for conversion of notes 
    $636,866  

The
accompanying notes are an integral part of these financial statements

F-6

JUPITER
NEUROSCIENCES, INC.

NOTES
TO FINANCIAL STATEMENTS

December
31, 2024 and 2023

Note
1 – Organization and Description of Business

Jupiter
Neurosciences, Inc. (the “Company”) is a clinical stage research and development pharmaceutical company located in Jupiter,
Florida. The Company